ArticleEuropean journal of clinical nutrition2025
Sociodemographic and clinical factors associated with low muscle mass and composition in people treated with (chemo)radiotherapy for lung cancer.
Article in European journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Body Composition in Resectable Non-Small Cell Lung Cancer Patients With Preoperative Sarcopenia: A Propensity-Matched Analysis.Journal of cachexia, sarcopenia and muscle · 2026Article
- Intervention strategies for cancer-related sarcopenia: a scoping review.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThis study examined (1) associations between sociodemographic and clinical variables with low muscle mass and radiodensity and their loss relative to treatment commencement in patients with lung cancer; and (2) the magnitude of change in muscle mass and association with treatment outcomes and survival.
methodsProspective study in patients planned for curative (chemo)radiotherapy for lung cancer. Low skeletal muscle mass and radiodensity and muscle loss were determined from pre- and post-treatment computed tomography images. Sociodemographic, clinical, functional, nutritional, physical activity and alternate body composition were assessed pre-treatment. Logistic and linear regression and Fisher's exact tests were used to assess associations between variables and study outcomes. Cox proportional hazards models were fitted to examine associations with survival.
resultsOverall, 53 patients (62.3% male) with a mean age of 69 ± 9.3 years and 54.8% with stage III disease were included. Pre-treatment low calf circumference was associated with pre-treatment low muscle mass (p = 0.006). Higher comorbidity scores pre-treatment were associated with normal muscle radiodensity pre- and post-treatment (p = 0.015, p = 0.027, respectively). Pre-treatment low energy and protein intake were associated with low muscle radiodensity post-treatment. Muscle mass and radiodensity were not associated with survival or treatment outcomes.
conclusionsIn patients with lung cancer, there is some evidence anthropometric measures of muscle mass are suggestive of low muscle mass pre-radiotherapy, while low energy intake pre-treatment may indicate low muscle radiodensity after treatment. However, these findings are limited by the small sample size and further prospective studies with larger samples are required.
Indexed as
Identifiers
39614103What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.